Remimazolam: The future of its sedative potential

Remimazolam (CNS 7056) is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia – Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil. It is likely to be the sedative of the future, as preliminary phase II trials have shown minimal residual effects on prolonged infusions. It has potential to be used as a sedative in ICU and as a novel agent for procedural sedation. Unlike most rapidly acting intravenous sedatives available presently, the propensity to cause apnea is very low. Availability of a specific antagonist (flumazenil) adds to its safety even in cases of overdose. The present review discusses remimazolam's potential as a new drug in anesthesia along with the presently available literary evidence.

[1]  M. Worthington,et al.  A Phase Ib, Dose-Finding Study of Multiple Doses of Remimazolam (CNS 7056) in Volunteers Undergoing Colonoscopy , 2013, Anesthesia and analgesia.

[2]  A. Sinha,et al.  Outpatient endoscopic retrograde cholangiopancreatography: Safety and efficacy of anesthetic management with a natural airway in 653 consecutive procedures , 2013, Saudi journal of anaesthesia.

[3]  R. Eckenhoff,et al.  Anesthetic drug development: Novel drugs and new approaches , 2013, Surgical neurology international.

[4]  Gavin Kilpatrick,et al.  A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics , 2012, Anesthesia and analgesia.

[5]  Gavin Kilpatrick,et al.  A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part II. Population Pharmacokinetic and Pharmacodynamic Modeling and Simulation , 2012, Anesthesia and analgesia.

[6]  K. Olkkola,et al.  Enhancement of GABAergic Activity: Neuropharmacological Effects of Benzodiazepines and Therapeutic Use in Anesthesiology , 2011, Pharmacological Reviews.

[7]  T. McDowell,et al.  Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures. , 2010, IDrugs : the investigational drugs journal.

[8]  R. Upton,et al.  Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. , 2010, British journal of anaesthesia.

[9]  R. Upton,et al.  Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep. , 2009, British journal of anaesthesia.

[10]  C. Grant,et al.  A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems , 2008, British journal of pharmacology.

[11]  Gavin Kilpatrick,et al.  CNS 7056: A Novel Ultra–short-acting Benzodiazepine , 2007, Anesthesiology.

[12]  C. Tuite,et al.  Sedation and analgesia in interventional radiology. , 2005, Seminars in interventional radiology.